933 days ago
GlaxoSmithKline (GSK) has announced its first quarter of the year results and that it reconfirms its full-year 2022 guidance. We are well ahead on this share tip where we are also drinking our own medicine so what to do now?
1208 days ago
GlaxoSmithKline (GSK) has announced second quarter of the year results, including stating “strong commercial execution” and “we are likely to deliver full-year Adjusted EPS towards the better end of our guidance range”. So where now for the shares?, with they currently having responded back up to 1400p.
1232 days ago
Joshua and I are about to have pancakes and a swim and then set out on the next leg of our road trip. A few photos from yesterday’s tearful encounters are HERE. In today’s podcast, I look at the smears that establishment folk like Alex Brummer are using to defend an establishment woman who has failed to deliver, the grotesquely overpaid CEO of GlaxoSmithKline (GSK) Emma Walmsley. I want her to pack her bags too and explain why she should.
1249 days ago
In today’s bearcast I consider Verditek (VDTK), GlaxoSmithKline (GSK), Sosandar (oink, oink) First Property (FPO) , Remote Monitored Systems (RMS) and MyHealthChecked (MHC).
2883 days ago
You want your share tip of the year to have the potential to double or treble. You will not get that with GlaxoSmithKline (GSK). Equally it is incredibly unlikely that you might lose 75% of your cash on Glaxo. Elephants do not gallop eith forwards or backwards. My third tip of the year is a stock that could lose 75% and become a cash shell. But it is also one that could easily treble and I think he odds are on the treble not the collapse. I refer to Wishbone Gold (WSBN)
2984 days ago
It is great to see that one of the UK's largest companies, GlaxoSmithKline (GSK) has a new CEO who has a cracking CV and and has without doubt been appointed on merit. Oh... and she wears a skirt, that is to say that she is a woman, Emma Walmsley. I wish her well. Emma demonstrates a couple of things which will horrify the liberal left.
3042 days ago
Barely a day goes by without the biased BBC serving up another reason to scrap the regressive poll tax that is the license fee. Yesterday it was its dire coverage of the Islamofascist butchers of ISIS. Today it is that old chestnut Brexit, you know that referendum where the sans culottes told the establishment and the liberal media where to stick it. The BBC is not listening. So GlaxoSmithKline has today announced it is investing £275 million in Britain creating thousands of jobs. Great news. er... The BBC tweeted this
4194 days ago
Robert Sutherland Smith is again proving that he is still alive with another guest post. Robert started his City career the year before I was born and is, I think, 157 years old. Fear not. He is very much alive and kicking. He and I have worked together for almost eight years at t1ps.com . He is my friend and he is a very funny and intelligent chap. He is now branching out to celebrate his 158th by doing some freelance writing over at various places ( including Shareprophets.com naturally) on FTSE 350 Income stocks. Robert is a speaker at the UKInvestor Show on April 5th 2014. He is a great one for focussing on yield. RSS today looks at GlaxoSmithKline. RSS writes:
The latest information and news emerging from GlaxoSmithKline (GSK) is of encouragement to investors generally but to dividend investors most particularly. Although the company is one of the stock markets dividend yield staple, with a long established reputation for cash generation, a glance at the trends in its cash flow statements is a bit disconcerting. Whilst investment spending over the last three years has been rising (that includes capital expenditure) operating cash flow, the stuff that finances it (along with dividend payments to ordinary shareholders) has been declining; and significantly so, last year.
4335 days ago
Robert Sutherland Smith started his City career the year before I was born. He is, I think, 157 years old. He and I have worked together for almost eight years. at t1ps. He is my friend and he is a very funny and intelligent chap. He is now branching out to celebrate his 158th by doing some freelance writing over at TradingResearchPoint on FTSE 350 Income stocks. He is a great one for focussing on yield. He is also going to do a monthly column for me on this blog on the subject that really interests him, life on Hampstead Heath. I am sure we all look forward to “Pond Life.” RSS today looks at GlaxoSmithKline and starts with a touch of comedy. He is a funny chap RSS.
Medical matters are on my mind as I have the Norovirus. But it takes more than that to stop me writing about companies but naturally my mind turns to drugs. Well I was a young man in the sixties – the 1960s not the 1860s before you ask. Talking of ancient history, the market long ago abandoned the assumption that GlaxoSmithKline (GSK) would automatically build a pathway for shareholders to a starlight future of endless profits and earnings growth, by simply spending 15% of its sales revenue on R&D, and turning that into an approved blockbuster therapy every few years. In truth, costs rose and progress became more difficult – the return on R&D capital was not acceptable.
